Fig. 1

First-line treatment regimens received in the pre-ICI and post-ICI periods by histology. ^a Patients who discontinued a platinum-based chemotherapy and initiated an ICI other than pembrolizumab without any progression reported prior to ICI start. Under these circumstances, the ICI was considered as part of the first-line regimen. ^b ICI monotherapy other than pembrolizumab (i.e., not indicated in first line); patients in this category were likely to have been refractory to a previous multimodal treatment administered for non-metastatic disease. ALK Anaplastic lymphoma kinase, EGFR Epidermal growth factor receptor, ICI Immune checkpoint inhibitor; NSQ Non-squamous cell, SQ Squamous cell, TKI Tyrosine kinase inhibitor